Register now
To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.
Already have an account?
If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.
SYMBICORT TURBUHALER:
The #1 dispensed
ICS/LABA1
The #1
dispensed
ICS/LABA1
The treatment of asthma in patients 12 years and older with reversible obstructive airways disease.
The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.
Review the CTS Summary Booklet for guidance updates on budesonide/formoterol therapy in mild and moderate asthma, and encourage your patients to speak with a doctor if their current asthma treatment plan is not working.
COPD: chronic obstructive pulmonary disease; CTS: Canadian Thoracic Society; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist.
References:
SYMBICORT® and TURBUHALER® are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
